Late stage tumor regression after PD-L1 blockade with a concurrent OX40 agonist.
Document Type
Article
Publication Date
12-18-2018
Publication Title
Cancer Immunol Res
Abstract
The protective capability of tumor antigen-specific T cells is regulated by costimulatory and inhibitory signals. Current approaches in cancer immunotherapy seek to restore the function of unresponsive T cells by blocking inhibitory pathways. In contrast, providing exogenous costimulatory signals to T cells also enhances antitumor functionality. By combining these two clinical approaches, we demonstrate the synergy of targeting PD-L1 together with the costimulatory molecule OX40, to enhance antitumor immunity. Concurrently blocking PD-L1 and providing a costimulatory agonist to OX40 increased the presence and functionality of tumor antigen-specific CD8+ T cells with simultaneous enhancement of T-helper type 1 (Th1)-skewed CD4+ T cells. This shift was functionally supported by increased glucose metabolism of antigen-specific CD8+ T cells and the acquisition of granzyme B by regulatory T cells. Together, this mechanism promoted tumor regression of late-stage tumors beyond that achieved by either blockade as monotherapy. These findings indicate that targeting both T-cell intrinsic (OX40) and extrinsic (PD-L1) regulatory molecules increases the bioenergetic potential of T cells, thereby expanding functional and tumor antigen-specific T cells.
Clinical Institute
Cancer
Department
Oncology
Department
Earle A. Chiles Research Institute
Recommended Citation
Polesso, Fanny; Weinberg, Andrew D; and Moran, Amy E, "Late stage tumor regression after PD-L1 blockade with a concurrent OX40 agonist." (2018). Articles, Abstracts, and Reports. 910.
https://digitalcommons.providence.org/publications/910
